Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Hypertrophic Cardiomyopathy Clinical Trials

14 recruiting trials for Hypertrophic Cardiomyopathy. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
14
Total Trials
14
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06573723

Institutional Registry of Rare Diseases

The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD)....

Sponsor: Hospital Italiano de Buenos AiresEnrolling: 3801 location
RECRUITINGNCT04464655

A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease

This study aims to identify and assess new CMR techniques that can improve current CMR protocols.

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health CentreEnrolling: 21301 location
RECRUITINGNCT05818605

Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy

The EXCITE-HCM study is a randomized, controlled, blinded clinical trial designed to evaluate the effect of moderate intensity exercise training versus usual physicial activity on...

Sponsor: University of California, San FranciscoEnrolling: 701 location
RECRUITINGNCT05884892

Egyptian Hypertrophic Cardiomyopathy Program

Egyptian HCM program aims at defining incidence, severity, phenotype, genotype and determinants of the disease in Egypt, and providing state-of-the-art treatment strategies...

Sponsor: Magdi Yacoub Heart FoundationEnrolling: 20001 location
RECRUITINGNCT01091480

French Hypertrophic Cardiomyopathy Observatory

Hypertrophic cardiomyopathy (Hypertrophic CardioMyopathy=HCM) remains a poorly understood disease with an assumption insufficiently codified. There is no data available in France...

Sponsor: French Cardiology SocietyEnrolling: 6001 location
RECRUITINGNCT02804269

Molecular and Imaging Studies of Cardiovascular Health and Disease

Biobank is a program which collects biological samples, health information and imaging data from consented patients and stored them at the core facility. These information would...

Sponsor: National Heart Centre SingaporeEnrolling: 50001 location
RECRUITINGNCT05939700

Mavacamten Pregnancy Surveillance Program

The purpose of this observational pregnancy safety study is to assess maternal, fetal, and infant outcomes after exposure to mavacamten at any time during pregnancy and/or...

Sponsor: Bristol-Myers SquibbEnrolling: 201 location
RECRUITINGNCT03362164

Evaluation of HEArt invoLvement in Patients With FABRY Disease

This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as well as terminal heart failure in patients with Fabry disease.

Sponsor: Wuerzburg University HospitalEnrolling: 6501 location
RECRUITINGNCT03846297

Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy

The main objective of the study is to improve implantable cardioverter defibrillator (ICD) implantation decision-making processing relevance by developing a new prediction model...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 20001 location
RECRUITINGNCT04684290

Surgical Septal Myectomy vs Percutaneous Transluminal Alcohol Septal Ablation in Patients With Hypertrophic Obstructive...

The aim of this randomized trial is to compare the improvement in exercise capacity among patients with highly symptomatic hypertrophic obstructive cardiomyopathy despite optimal...

Sponsor: St. Antonius HospitalEnrolling: 1001 location
RECRUITINGNCT02432092

Pediatric Cardiomyopathy Mutation Analysis

The goal of this protocol is to obtain information from individuals with cardiomyopathy and from their families in order to elucidate the molecular genetics of this disorder. This...

Sponsor: Indiana UniversityEnrolling: 3001 location
RECRUITINGNCT06490250

Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises in Hypertrophic Cardiomyopathy Patients

The study aims to compare the effects of inspiratory muscle training and Baduanjin exercises on pulmonary function, exercise capacity, and quality of life in patients with...

Sponsor: Istanbul University - CerrahpasaEnrolling: 511 location
RECRUITINGNCT06610019

Cardiovascular Multimodality Imaging Study

Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis. There is increased risk for cardiovascular...

Sponsor: Montefiore Medical CenterEnrolling: 50001 location
RECRUITINGNCT06409585

Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition

Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as...

Sponsor: University of EdinburghEnrolling: 2901 location

Frequently Asked Questions

There are currently 14 clinical trials for Hypertrophic Cardiomyopathy, with 14 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Hypertrophic Cardiomyopathy, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Hypertrophic Cardiomyopathy, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.